Current status of immunotherapy for gastrointestinal stromal tumor. (Q39130013)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

2 April 2020

title

Current status of immunotherapy for gastrointestinal stromal tumor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

2 April 2020

author name string

Y Tan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

2 April 2020

J C Trent

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

2 April 2020

D A Kerr

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

2 April 2020

A E Rosenberg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

2 April 2020

publication date

10 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

2 April 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

2 April 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

2 April 2020

page(s)

130-133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

Gastrointestinal stromal tumors: molecular markers and genetic subtypes.

2 April 2020

cites work

1 reference

Managing GIST in the imatinib era: optimization of adjuvant therapy

21 January 2018

1 reference

Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies

21 January 2018

1 reference

The immune system and gastrointestinal stromal tumor: a wealth of opportunities

21 January 2018

1 reference

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors

21 January 2018

1 reference

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

21 January 2018

1 reference

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

21 January 2018

1 reference

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

21 January 2018

1 reference

Novel treatment targets in sarcoma: more than just the GIST

21 January 2018

1 reference

PDL1 expression is an independent prognostic factor in localized GIST.

21 January 2018

1 reference

Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade

21 January 2018

1 reference

Exploiting antitumor immunity to overcome relapse and improve remission duration

21 January 2018

1 reference

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth

21 January 2018

1 reference

Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor

21 January 2018

1 reference

Immunotherapeutic Approaches to Sarcoma

21 January 2018

1 reference

7 January 2021

PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors

1 reference

7 January 2021

Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors

1 reference

7 January 2021

Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors

1 reference

7 January 2021

Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors

1 reference

7 January 2021

Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28186088

12 December 2020

inferred from PubMed ID database lookup

Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28186088

12 December 2020

inferred from PubMed ID database lookup

Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28186088

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/CGT.2016.58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28186088 AND SRC:MED&resulttype=core&format=json

2 April 2020

1 reference